Ernexa CEO says ERNA-101 aims to boost combination immunotherapy in solid tumors

PUBT · 2d ago
Ernexa CEO says ERNA-101 aims to boost combination immunotherapy in solid tumors
  • Ernexa management outlined a strategy to position ERNA-101 as a combination partner for immunotherapies by targeting the immunosuppressive tumor microenvironment.
  • Preclinical ovarian cancer data highlighted complete tumor elimination with PD-1 blockade, including independent validation showing durable clearance in about two-thirds of treated animals.
  • Manufacturing process development completed; engineering batch production started; IND submission targeted for Q3 2026.
  • Phase 1 first-in-human study anticipated in Q4 2026, with an initial commercial focus on about 15,000 annual U.S. platinum-resistant ovarian cancer diagnoses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240920PRIMZONEFULLFEED9767681) on July 24, 2026, and is solely responsible for the information contained therein.